Trusted by over 15 Million Traders
The Most Awarded Broker
for a Reason
market news
【XM Market Review】--Best 7 Pharma Stocks for December 2025
Risk Warning:
The purpose of information release is to warn investors of risks and does not constitute any investment advice. The relevant data and information are from third parties and are for reference only. Investors are requested to verify before use and assume all risks.
Hello everyone, today XM Forex will bring you "【XM Market Review】--Best 7 Pharma Stocks for December 2025". I hope it will be helpful to you! The original content is as follows:
Healthcare stocks have tremendous growth potential but also face challenges from government policies, especially over the next few years. Still, the healthcare sector is growing faster than the broader economy, and investors have many exciting ways to participate.
What are Healthcare Stocks?
Healthcare stocks are publicly listed www.xmmaker.companies active in the healthcare sector. They cover a broad range of subsectors and www.xmmaker.companies, including pharmaceuticals, medical devices, biotech, healthcare providers, health insurers, and pharmacy benefit managers (PBMs).
Why Should You Consider Investing in Healthcare Stocks?
Healthcare stocks are an excellent defensive investment to protect a portfolio against economic uncertainty, recessions, and, to a lesser extent, inflation. Consumers with prescription medication or medical needs cannot alter their treatment due to economic swings, making revenue streams for healthcare stocks more stable.
Here are a few things to consider when evaluating healthcare stocks:
- Invest in healthcare stocks with a healthy pipeline of medications and treatments in Phase I, Phase II, and Phase III trials.
- Evaluate the current products and how they address the needs of the current healthcare situation.
- Ensure a healthy pidend yield to www.xmmaker.compensate for the added political and regulatory risks.
- Analyze the balance sheet and focus on free cash flow and overall debt levels.
What are the Downsides of Healthcare Stocks?
Investing in healthcare stocks requires considering political and regulatory risks. They are unexpected developments that can swiftly reverse momentum and cause double-digit selloffs. High research and development costs, expiring patents, and stiff www.xmmaker.competition are additional downsides of healthcare stocks.
Here is a shortlist of currently attractive healthcare stocks to consider:
- Pfizer (PFE)
- Vertex Pharmaceuticals (VRTX)
- Fresenius Medical Care (FMS)
- Elevance Health (ELV)
- BioMarin Pharmaceutical (BMRN)
- Merck & Co (MRK)
- Cencora (COR)
Update on My Previous Best Healthcare Stocks to Buy Now
In our previous installment, I highlighted the upside potential of Pfizer and Vertex Pharmaceuticals.
Pfizer (PFE) - A long position in PFE between $23.91 and $25.52
PFE is up nearly 2% since my recommendation, and bullish catalysts dominate. So, I will hold on to my position.
Vertex Pharmaceuticals (VRTX) - A long position in VRTX between $91.59 and $95.29
VRTX advanced over 2%, and I maintain my long position, as the bullish narrative remains intact.
Fresenius Medical Care Fundamental Analysis
Fresenius Medical Care (FMS) provides kidney dialysis services primarily for patients with end-stage renal disease (ESRD). It maintains a network of over 4,170 outpatient dialysis centers, treating over 345,000 patients. It also operates 42 production sites, and Fresenius Medical Care is also a www.xmmaker.component of the DAX 40.
So, why am I bullish on FMS after its post-earnings correction?
I am bullish on Fresenius Medical Care for its unique position in the healthcare industry, as it provides a life-saving service that is not affected by economic conditions. Valuations are low, and FMS maintains a double-digit earnings-per-share growth rate. It uses insights into caregiver and patient needs to develop better technology to treat ESRD patients, ensuring its products, which it also sells to www.xmmaker.competitors, are at the cutting edge of medical technology. Its advancements into at-home treatments are an underappreciated bullish catalyst.

Fresenius Medical Care Fundamental Analysis Snapshot
The price-to-earnings (P/E) ratio of 16.85 makes FMS an inexpensive stock. By www.xmmaker.comparison, the P/E ratio for the S&P 500 is 30.61.
The average analyst price target for FMS is $29.36. This suggests moderate upside potential with limited downside risk.
Fresenius Medical Care Technical Analysis

Fresenius Medical Care Price Chart
- The FMS D1 chart shows price action at its descending 38.2% Fibonacci Retracement Fan level with a pending breakout.
- It also shows Fresenius Medical Care breaking out above its horizontal support zone.
- The Bull Bear Power Indicator is bullish with an ascending trendline.
My Call on Fresenius Medical Care
I am taking a long position in FMS between $23.50 and $24.20. I am buying into its unique positioning as a life-saving healthcare www.xmmaker.company and its advancements into at-home treatments.
- FMS Entry Level: Between $23.50 and $24.20
- FMS Take Profit: Between 429.36 and $30.24
- FMS Stop Loss: Between $21.40 and $21.84
- Risk/Reward Ratio: 2.79
Elevance Health Fundamental Analysis
Elevance Health (ELV) is a health insurance www.xmmaker.company serving more than 46 million medical members. It is the exclusive licensee of the Blue Cross Blue Shield brand in 14 states. ELV is also a www.xmmaker.component of the S&P 500 Index.
So, why am I bullish on Elevance Health following its post-earnings slide?
Reports indicating the White House may unveil a health policy framework that includes a 2-year extension of Affordable Care Act (ACA) premium subsidies boosted Elevance Health from its post-earnings slide. I remain bullish on its overall network, as it serves approximately one in three inpiduals in states where it operates, making it the second-largest insurer, lagging only national insurer UnitedHealth, despite a limited geographic footprint.

Elevance Health Fundamental Analysis Snapshot
The price-to-earnings (P/E) ratio of 13.80 makes ELV an inexpensive stock. By www.xmmaker.comparison, the P/E ratio for the S&P 500 is 30.61.
The average analyst price target for Elevance Health is $387.16. It suggests good upside potential with reasonable downside risks.
Elevance Health Technical Analysis

Elevance Health Price Chart
- The ELV D1 chart shows price action breaking out above its ascending Fibonacci Retracement Fan.
- It also shows Elevance Health inside a bullish price channel.
- The Bull Bear Power Indicator is bullish with an ascending trendline.
My Call on Elevance Health
I am taking a long position in Elevance Health between $332.21 and $341.89. I am bullish on its ambitious 12% annualized EPS growth and its value-based, risk-sharing relationships to decrease overall healthcare costs.
- ELV Entry Level: Between $332.21 and $341.89
- ELV Take Profit: Between $375.55 and $387.16
- ELV Stop Loss: Between $314.08 and $323.79
- Risk/Reward Ratio: 2.39
The above content is all about "【XM Market Review】--Best 7 Pharma Stocks for December 2025", which is carefully www.xmmaker.compiled and edited by XM Forex editor. I hope it will be helpful for your trading! Thank you for your support!
Disclaimers: XM Group only provides execution services and access permissions for online trading platforms, and allows individuals to view and/or use the website or the content provided on the website, but has no intention of making any changes or extensions, nor will it change or extend its services and access permissions. All access and usage permissions will be subject to the following terms and conditions: (i) Terms and conditions; (ii) Risk warning; And (iii) a complete disclaimer. Please note that all information provided on the website is for general informational purposes only. In addition, the content of all XM online trading platforms does not constitute, and cannot be used for any unauthorized financial market trading invitations and/or invitations. Financial market transactions pose significant risks to your investment capital.
All materials published on online trading platforms are only intended for educational/informational purposes and do not include or should be considered for financial, investment tax, or trading related consulting and advice, or transaction price records, or any financial product or non invitation related trading offers or invitations.
All content provided by XM and third-party suppliers on this website, including opinions, news, research, analysis, prices, other information, and third-party website links, remains unchanged and is provided as general market commentary rather than investment advice. All materials published on online trading platforms are only for educational/informational purposes and do not include or should be considered as applicable to financial, investment tax, or trading related advice and recommendations, or transaction price records, or any financial product or non invitation related financial offers or invitations. Please ensure that you have read and fully understood the information on XM's non independent investment research tips and risk warnings. For more details, please click here
CATEGORIES
News
- 【XM Decision Analysis】--BTC/USD Forex Signal: Bitcoin Breaks $107,000, How Much
- 【XM Group】--WTI Crude Oil Weekly Forecast: Solid Trading High Followed by Revers
- 【XM Group】--AUD/USD Forecast: Holds in Consolidation
- 【XM Market Review】--GBP/USD Forex Signal: Bullish Momentum Ahead of BoE Decision
- 【XM Forex】--AUD/USD Forex Signal: Downtrend Intact, Low Volume Expected